OSE Immunotherapeutics SA presented new clinical and translational data on Tedopi? (neoepitope-based cancer vaccine) in non-small cell lung cancer and the latest data from BiCKI?-IL-7 (bifunctional therapy targeting PD-1 and IL-7) preclinical programs at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington D.C. (and virtually) held on November 10 ? 14, 2021. The poster entitled: ?Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 (Tedopi?) vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial? included clinical data from a translational analysis performed from HLA-A2+ patients treated with Tedopi? in the Atalante-1 Phase 3 clinical trial. Available tumor biopsies at initial diagnosis were analyzed to determine the expression of the tumor-associated antigens (TAAs) and to identify other tumor factors associated with long-term survival. This translational analysis showed: A high/high Immunoscore? associated with high CD8 T-cell tumor infiltration, and a higher proportion of CD8 cells interacting with PD-L1 cells in a patient with a partial response; Transcriptomic data have shown an activated macrophage pathway. High IFN-? and expanded immune gene signatures scores were observed in long-term surviving patients with secondary resistance to immune checkpoint blockade. The Phase 3 clinical trial Atalante-1 demonstrated a favorable benefit/risk ratio of Tedopi? versus standard of care (SoC) docetaxel or pemetrexed in advanced HLA-A2+ NSCLC patients with secondary resistance to immune checkpoint inhibitors (data presented at the 2021 European Society for Medical Oncology Congress). The poster entitled: ?Long-term anti-tumor preclinical efficacy of an optimized anti-PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity? has described a monotherapy with BiCKI?-IL-7, an anti-PD1/IL-7 bifunctional monoclonal antibody, that induces long-term survival, proliferation and responses without signs of exhaustion of T cells as well as robust in vivo anti-tumor memory response in different preclinical models.